Top Seattle, WA Biotech Companies (44)
Trusted by the world's leading organizations, Point B is a consulting firm that works at the intersection of expertise, industry insight, and transformative technology. This collaborative approach enables you to solve your most important challenges, by bringing together the right mix of talent and technology to deliver greater value and impact. With over 850 associates in the US and 3000+ consultants around the world through our Nextcontinent partnership, we work where you do to deliver the change you seek.
_5.png)
Spiral Genetics is a bioinformatics company that develops high performance software for analyzing next-generation sequencing data. We specialize in large-scale DNA data analysis for medical, pharmaceutical and agricultural research. As a company, we value technological and scientific excellence and are constantly pushing the envelope.
Dendreon is a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy. Dendreon’s flagship product, PROVENGE (sipuleucel-T), was the first FDA-approved immunotherapy made from a patient’s own immune cells. More than 40,000 men with advanced prostate cancer have been prescribed PROVENGE in the U.S. since 2010. Dendreon also is evaluating the use of PROVENGE in early-stage prostate cancer, with the hope of curing more men of the disease. Dendreon is headquartered in Seal Beach, Calif.
Aiberry is a dynamic startup creating an innovative and practical mental health screening solution. Its platform improves efficiency and saves time for healthcare providers with cutting-edge AI technology, based on two decades of research bundled into a powerful solution that helps providers better serve their patients. Its Machine Learning (ML) pipelines are designed to eliminate biases, including those related to age, gender, sexual orientation and race. Aiberry's distinctive, multi-modal approach evaluates an individual's mental health by analyzing text, audio, and video cues during a bot-administered interview. The status quo of depression measurement requires individuals to self-rate the frequency and severity of their depression symptoms by picking a “best describes you” answer from a series of multiple-choice questions. Meanwhile, Aiberry’s app offers the option of a novel AI assessment featuring a friendly digital animation called “Botberry” that encourages users to talk about themselves in their own words.
We are developing next-generation, multi-payload antibody-drug conjugates (ADCs) that feature differentiated payload and linker technologies. This enables targeted delivery of drug combinations to tumor cells to maximize therapeutic benefit for cancer patients. Our lead program is a dual-payload HER2-targeted ADC.
Resolve Therapeutics is a biotechnology company developing an exciting new biologic compound for the treatment of lupus that inhibits a key upstream step in the interferon cascade. The company is based on technology and compounds exclusively licensed from the University of Washington. The company will develop these compounds through early clinical testing and partner with a pharmaceutical company for late stage clinical development and commercialization.
ProCogia is a market-leading data consultancy fielding a team of agnostic data experts, delivering projects at clients including Microsoft, T-Mobile, Getty Images and Roche. Our dedicated team help to deliver end-to-end data solutions using our Data Operations, Data Engineering, BI, Analytics and Data Science expertise. These capabilities help to deliver highly scalable data solutions that leverage the full potential of your data. To build agnostic data solutions ProCogia are partnered with AWS, Microsoft, Snowflake & RStudio. We are headquartered in Vancouver, BC with offices in Seattle, New York, Boston, Toronto, Calgary, India, and Ireland. We work with clients across numerous sectors including Telecom, Pharma, Biotechnology, Retail, Logistics, Technology, Financial Services, Media & non-profit.
Halo-Bio RNAi Therapeutics Inc. is an early stage company.
InBios International Inc. specializes in the design, development and manufacture of diagnostic assays for emerging infectious diseases and biothreats. Located in Seattle, Washington, InBios offers superior quality products which are accurate, easy to use and cost effective. InBios is GMP compliant, FDA registered, USDA licensed and ISO 13485:2016 certified. For more information, visit http://www.inbios.com.
ShapeTX is pioneering the field of programmable RNA medicines to repair the genetic causes of diseases. By merging innovations in AI and RNA technology to generate and analyze hundreds of billions of therapeutic possibilities, ShapeTX is developing breakthroughs in RNA editing, next-generation AAVs, and disruptive gene therapy manufacturing. The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer’s, Parkinson’s, and many more.
Oscine Therapeutics is a new biotechnology company based on discoveries made and developed at the University of Rochester Medical Center
Sana Biotechnology is focused on utilizing engineered cells as medicines for patients. The ability to modify genes and use cells as medicines will be one of the most important advances in healthcare over the next several decades. Sana is building differentiated capabilities across the spectrum of cell and gene therapy. Three aspirations drive Sana as we look to discover treatments for patients with poor outcomes or currently untreatable diseases. The first is the ability to repair and control the genes in any cell in the body. We are advancing novel delivery technologies with the goal of being able to deliver any payload to any cell in a specific, predictable, and repeatable manner, paving the way for next-generation in vivo gene therapy. Next is the ability to differentiate pluripotent stem cells ex vivo into immune-cloaked functional cells with the aspiration of being able to replace any missing or damaged cells in the body. Last is a belief we can enable broader access to our therapies through focusing on scalable manufacturing solutions, the cost of manufacturing, and aligning with key stakeholders. Sana launched in early 2019 and has over 350 employees in Seattle, Cambridge, and South San Francisco. Sana was founded with the long view – bringing together great people and the best technologies to deliver on the challenging promise of using engineered cells to meaningfully change the outcome of many human diseases.
NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research. The company's technology enables a wide variety of basic research and translational medicine applications. NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection. In 2019, the company launched the GeoMx™ Digital Spatial Profiler enabling highly-multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections.
We sequence whole plasmids, amplicons, whole bacterial genomes, and colonies overnight, without the need for primers and minipreps. Plasmidsaurus is on a mission to accelerate new cures and promote a healthier planet by unlocking new levels of productivity in scientists using DNA tools to bring their ideas to life. The company’s DNA sequencing services are used daily by thousands of innovators, including Nobel prize winners, dynamic biotech startups, pharmaceutical companies, research labs, and DIY biohackers. Plasmidsaurus’s global network of labs operates day and night to enable world-changing discoveries. Sequence Everything!
Parse Biosciences is a Seattle-based startup providing researchers access to the most scalable single cell sequencing platform available. With technology founded on the principles of SPLiT-seq, published in Science in 2018, Parse Biosciences' mission is to accelerate progress in scientific research as well as human health. Single-cell sequencing has already enabled groundbreaking discoveries that have led to new understandings in cancer treatment, tissue repair, stem cell therapy, the immune system and much more. At Parse Biosciences we provide researchers with the ability to perform single cell sequencing with unprecedented scale and ease.
Myosana Therapeutics, Inc. is pioneering efforts in developing non-viral targeted gene therapy for skeletal muscle and cardiac diseases. Our current focus is Duchenne muscular dystrophy (DMD) but our platform is applicable to any genetic muscle disease. Current gene therapy for skeletal and cardiac muscle diseases uses Adeno Associated Virus (AAV) to deliver small healthy genes or portions of large genes, to the cells that contain unhealthy (mutated) genes. AAV has numerous limitations, including limited gene size capacity (5 kilobases), precluding its use for many larger genes like dystrophin. Furthermore, many individuals may have naturally occurring antibodies against AAV or will develop antibodies after their first treatment, limiting treatment to a single dose. The Myosana Platform Technology bypasses the limitations of AAV delivery and, therefore, is much more versatile. • The Myosana platform does not use viruses to deliver genes to the cells. • The new technology can deliver genes of any size. • The Myosana Non-Viral delivery method is much less likely to elicit an immune response, enabling repeated dosing over months or years. • The Myosana platform targets the healthy gene to skeletal and cardiac muscle cells. The novel gene therapy approach we have developed will provide new treatments for many diseases of skeletal and cardiac muscle. Our current focus is DMD, but we expect to use the platform to treat other muscular dystrophies and congenital myopathies.
At Inventprise, developing innovative and widely available vaccines is in our DNA. By producing targeted vaccines for populations worldwide, we're addressing global health inequalities and empowering people to live healthy lives—no matter where they live. Headquartered in Redmond, WA, our goal is to deliver widely-available, effective vaccines at large-scale to Low and Middle Income Countries, as well as populations in the U.S. and around the world. Inventprise is committed to creating a diverse and inclusive workplace, where our people are inspired to do their best work. We’re proud to have some of the world’s most qualified industry scientists, researchers, and manufacturing professionals on our team, and strive to create a vibrant, dynamic presence in the Washington State Life Sciences environment. Learn more about Inventprise and view open roles at www.inventprise.com/careers to become a part of our growing team.
Cajal Neuroscience is a drug discovery company focused on neurodegenerative disease.
Avalyn is a clinical-stage biopharmaceutical company developing inhaled therapies to treat rare respiratory diseases, including idiopathic pulmonary fibrosis and other interstitial lung diseases. Our lead candidate, AP01, is a Phase 2b-ready inhaled formulation of pirfenidone in development for the treatment of pulmonary fibrosis.
Adaptive Symbiotic Technologies is a dynamic agricultural biotech company based in Seattle, Washington, U.S.A. We focus on the research and production of symbiotic plant microbes as agricultural crop treatments for farmers. This symbiotic relationship between crops and microbes allows plants to tolerate abiotic stress and increase uptake of soil nutrients naturally. This dynamic relationship is a cooperative approach to making plants healthier and more adaptable to increasing climate changes around the globe. We are continually searching for new microbial symbionts and organic plant treatments to increase agricultural sustainability and farmers' profitability. Our intent is to make this technology available to small and large-scale farmers in first world and developing nations to help increase crop yields and decrease human hardship.
